Nasodine Retail Launch Begins With Up to 700 Stores

Nasodine Moves Beyond Direct-to-Consumer Sales

Firebrick Pharma Limited (ASX:FRE) is taking Nasodine into the US retail pharmacy market, shifting the product beyond its existing direct-to-consumer channel after US online sales grew by more than 200% in FY26. The company’s board has approved a phased plan beginning with independent pharmacy groups and potentially progressing to wholesale banner groups and major retail chains.

The opportunity emerged from Firebrick’s attendance at the NACDS retail trade expo in Boston in August, where it met more than 20 retail pharmacy groups. Firebrick said up to six independent regional groups, representing around 700 stores, expressed strong intent to place early orders. That language matters: the announcement does not disclose signed distribution agreements or confirmed purchase orders.

Three-Phase US Distribution Plan

Phase 1 will focus on the independent groups already engaged by Firebrick. Later phases, with timing to be determined during 2027, would target wholesale banner groups representing about 7,000 stores and major retail chains representing a further 25,000 stores. The company said its proposed pricing was well received and that Nasodine’s positioning as a cosmetic nasal cleanser was not considered a barrier by the pharmacy groups it met.

Al Moghaddam, who previously served as Firebrick’s US-based non-executive director, has been appointed US Commercial Director and Executive Director of Firebrick Pharma, Inc. He is charged with leading the retail rollout and brings experience involving pharmacy chains including CVS and Walgreens, as well as wholesalers McKesson, Cardinal Health and Amerisource. Follow-on negotiations with regional groups have already begun, while retail packaging is being upgraded and manufacturing preparations are being scaled up.

Parent Company Economics Depend on US Execution

Firebrick says the US subsidiary is intended to become increasingly self-funded from sales, with logistics, sales and customer-service staff expected to be added beyond FY27. The Australian company would receive a 12% royalty and a 5% management fee on US sales, plus a 20% fee on manufacturing costs under the exclusive US manufacturing rights. It could also receive dividends from US profits, which Firebrick says could potentially support early profitability in Australia.

The commercial arrangement also carries a fixed and variable cost. Moghaddam will receive CAD12,000 a month, plus a 3% commission on monthly net sales attributable to US retail pharmacy, under an initial 12-month agreement that either party can terminate with 30 days’ notice. The filing does not quantify launch costs, expected revenue, manufacturing capacity or the working capital required to support the rollout.

Early Demand Still Needs to Become Orders

Firebrick’s US plan gives the Nasodine range a larger potential route to market, while the proposed throat spray and other products could provide pharmacies with a broader portfolio. Southeast Asian activities will continue under the company’s existing business development leadership. The immediate test, however, is narrower and more concrete: whether interest from the NACDS meetings converts into initial orders, repeat sales and a retail operation capable of funding itself.